Evidence map›Paper›PMID 41359345›Full record

ArticleHuman vaccines & immunotherapeutics2025

Effectiveness and safety of the recombinant zoster vaccine in adults aged ≥50 years with inflammatory bowel disease.

Hung Fu Tseng, Lina S Sy, Emily Rayens, Bradley K Ackerson, Jennifer H Ku, Jun Wu, Yi Luo, Yanjun Cheng, Avanish R Patel, Zendi Solano and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hung Fu TsengDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Lina S SyDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Emily RayensDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Bradley K AckersonDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Jennifer H KuDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Jun WuDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Yi LuoDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Yanjun ChengDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Avanish R PatelDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Zendi SolanoDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Justine De JesusDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Britta AmundsenDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Ana FloreaDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Elizabeth Chmielewski-YeeVaccines and Infectious Disease Epidemiology, GSK, Rockville, MD, USA.
Driss OraichiReal World Biostatistics, GSK, Rockville, MD, USA.
Harry SeifertGlobal Safety, GSK, Rockville, MD, USA.
Huifeng YunVaccines and Infectious Disease Epidemiology, GSK, Rockville, MD, USA.
Lei QianDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.ORCID 0000-0001-8001-3992

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adults with inflammatory bowel disease (IBD) face a higher risk of herpes zoster (HZ). We assessed the vaccine effectiveness (VE) of the recombinant zoster vaccine (RZV) in preventing HZ and the risk of flares post-immunization in adults aged ≥50 years with IBD. We conducted a matched cohort analysis at Kaiser Permanente Southern California. To evaluate VE, we included individuals aged ≥50 years with IBD who received 2 doses of RZV between 04/01/2018-12/31/2021 and followed them through 12/31/2022. These individuals were matched up to 1:3 to RZV-unvaccinated individuals on age, sex, race/ethnicity, condition (ulcerative colitis, Crohn's disease), IBD medication type, and index date (date of second dose among vaccinated individuals; same date assigned to unvaccinated match). Cox proportional hazards regression was used to estimate VE. To evaluate safety, we used self-controlled case series analysis (SCCS). The relative risk (RR) of flare was estimated using conditional Poisson regression, comparing the incidence of chart-confirmed IBD new-onset flares in the risk (30 days after each dose) versus comparison periods among individuals with ≥1 dose. In the VE evaluation cohort (2-dose vaccinated: N = 872, unvaccinated: N = 2,550), overall adjusted VE in preventing HZ was 65.1% (95% CI, 24.8-83.8). In SCCS analysis, among 1,199 individuals who received ≥1 dose of RZV, there was no increased risk of IBD flare observed within 30 days after vaccination (RR: 0.80; 95% CI, 0.47-1.35). In adults aged ≥50 with IBD, 2 doses of RZV effectively prevented HZ without increasing flare risk. These findings support current vaccination recommendations to prevent HZ in adults ≥50 years, including individuals with immunodeficiency or immunosuppression.

Indexed as

Herpes ZosterHerpes Zoster VaccineInflammatory Bowel DiseasesVaccine EfficacyAgedAged, 80 and overCaliforniaCohort StudiesFemaleHumansIncidenceMaleMiddle AgedVaccinationVaccines, SyntheticHerpes Zoster VaccineVaccines, SyntheticCrohn’s diseaseherpes zosterInflammatory bowel diseaserecombinant zoster vaccineulcerative colitisvaccination

Identifiers

PMID41359345
PMCPMC12688260

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.